SETD2 and cancer: Interestingly, SETD2 mutations, resulting in redistribution of H3K36me3, cause DNA hypermethylation at gene bodies in renal cell carcinoma51, contrasting with widespread promoter hypomethylation in NSD1-inactivated cancers.